This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Wenaweser, P. Articles by Windecker, S. Search for Related Content PubMed Articles by Wenaweser, P. Articles by Windecker, S.

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice

4-Year Results From a Large 2-Institutional Cohort Study

Peter Wenaweser, MD^_*, Joost Daemen, MD, Marcel Zwahlen, PhD, Ron van Domburg, PhD, Peter Jüni, MD, Sophia Vaina, MD, PhD, Gerrit Hellige, MD^_*, Keiichi Tsuchida, MD, Cyrill Morger, MD^_*, Eric Boersma, PhD, Neville Kukreja, MBBS, MRCP, Bernhard Meier, MD^_*, Patrick W. Serruys, MD, PhD and Stephan Windecker, MD^_*,_*

^_* Department of Cardiology, University of Bern, Bern, Switzerland
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands

Manuscript received March 18, 2008; revised manuscript received June 30, 2008, accepted July 1, 2008.

^_* Reprint requests and correspondence: Dr. Stephan Windecker, Department of Cardiology, University Hospital Bern, 3010 Bern, Switzerland (Email: stephan.windecker{at}insel.ch).

Objectives: We sought to determine the risk of late stent thrombosis (ST) during long-term follow-up beyond 3 years, searched for predictors, and assessed the impact of ST on overall mortality.

Background: Late ST was reported to occur at an annual rate of 0.6% up to 3 years after drug-eluting stent (DES) implantation.

Methods: A total of 8,146 patients underwent percutaneous coronary intervention with a sirolimus-eluting stent (SES) (n = 3,823) or paclitaxel-eluting stent (PES) (n = 4,323) and were followed up to 4 years after stent implantation. Dual antiplatelet treatment was prescribed for 6 to 12 months.

Results: Definite ST occurred in 192 of 8,146 patients with an incidence density of 1.0/100 patient-years and a cumulative incidence of 3.3% at 4 years. The hazard of ST continued at a steady rate of 0.53% (95% confidence interval [CI]: 0.44 to 0.64) between 30 days and 4 years. Diabetes was an independent predictor of early ST (hazard ratio [HR]: 1.96; 95% CI: 1.18 to 3.28), and acute coronary syndrome (HR: 2.21; 95% CI: 1.39 to 3.51), younger age (HR: 0.97; 95% CI: 0.95 to 0.99), and use of PES (HR: 1.67; 95% CI: 1.08 to 2.56) were independent predictors of late ST. Rates of death and myocardial infarction at 4 years were 10.6% and 4.6%, respectively.

Conclusions: Late ST occurs steadily at an annual rate of 0.4% to 0.6% for up to 4 years. Diabetes is an independent predictor of early ST, whereas acute coronary syndrome, younger age, and PES implantation are associated with late ST.

Key Words: drug-eluting stent • mortality • stent thrombosis

Abbreviations and Acronyms   ACS = acute coronary syndrome   ARC = Academic Research Consortium   ASA = acetylsalicylic acid   BMS = bare-metal stent(s)   CI = confidence interval   DES = drug-eluting stent(s)   MACE = major adverse cardiac event   MI = myocardial infarction   PES = paclitaxel-eluting stent(s)   SES = sirolimus-eluting stent(s)   ST = stent thrombosis   TIMI = Thrombolysis In Myocardial Infarction

This article has been cited by other articles:

				S. G. Ellis A Generation 2.5 Drug-Eluting Stent? J. Am. Coll. Cardiol. Intv., October 1, 2009; 2(10): 986 - 988. [Full Text] [PDF]

				W. Wijns and P. Kolh Appropriate myocardial revascularization: a joint viewpoint from an interventional cardiologist and a cardiac surgeon Eur. Heart J., September 2, 2009; 30(18): 2182 - 2185. [Full Text] [PDF]

				M. T. Roe, A. Y. Chen, C. P. Cannon, S. Rao, J. Rumsfeld, D. J. Magid, R. Brindis, L. W. Klein, W. B. Gibler, E. M. Ohman, et al. Temporal Changes in the Use of Drug-Eluting Stents for Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention From 2006 to 2008: Results From the Can Rapid risk stratification of Unstable angina patients Supress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) and Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (ACTION-GWTG) Registries Circ Cardiovasc Qual Outcomes, September 1, 2009; 2(5): 414 - 420. [Abstract] [Full Text] [PDF]

				A. A. Khattab, C. W. Hamm, J. Senges, R. Toelg, V. Geist, T. Bonzel, M. Kelm, B. Levenson, C. A. Nienaber, T. Pfannebecker, et al. Sirolimus-Eluting Stent Treatment at High-Volume Centers Confers Lower Mortality at 6-Month Follow-Up: Results From the Prospective Multicenter German Cypher Registry Circulation, August 18, 2009; 120(7): 600 - 606. [Abstract] [Full Text] [PDF]

				W. Wijns Late Stent Thrombosis After Drug-Eluting Stent: Seeing Is Understanding Circulation, August 4, 2009; 120(5): 364 - 365. [Full Text] [PDF]

				S. Cook and P. Wenaweser Off-Label Use and the Spectre of Drug-Eluting Stent Thrombosis Circ Cardiovasc Interv, August 1, 2009; 2(4): 273 - 276. [Full Text] [PDF]

				J. M. Lasala, D. A. Cox, D. Dobies, K. Baran, W. B. Bachinsky, E. W. Rogers, J. A. Breall, D. H. Lewis, A. Song, R. M. Starzyk, et al. Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries Circ Cardiovasc Interv, August 1, 2009; 2(4): 285 - 293. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]

				J. A. Ormiston and P. W.S. Serruys Bioabsorbable Coronary Stents Circ Cardiovasc Interv, June 1, 2009; 2(3): 255 - 260. [Full Text] [PDF]

				M. B. Leon, D. J. Allocco, K. D. Dawkins, and D. S. Baim Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 504 - 512. [Abstract] [Full Text] [PDF]

				S. S. Brar, M. B. Leon, G. W. Stone, R. Mehran, J. W. Moses, S. K. Brar, and G. Dangas Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1677 - 1689. [Abstract] [Full Text] [PDF]

				D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dorrler, T. Morath, A. Schomig, A. Kastrati, and N. von Beckerath Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur. Heart J., April 2, 2009; 30(8): 916 - 922. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]